Healthcare Industry News: influenza
News Release - April 3, 2006
MedImmune Adds Substantial Expertise to Commercial Organization With Appointment of Two New Vice PresidentsGAITHERSBURG, Md., April 3 (HSMN NewsFeed) -- MedImmune, Inc. (Nasdaq: MEDI ) today announced that it has added two leaders to its senior commercial management ranks. The new executive appointments are John J. Trizzino, vice president, trade and distribution, and Mark C. Twyman, vice president and general manager, vaccines. The addition of Mr. Trizzino and Mr. Twyman follows several recent senior-level appointments, including three previously announced leaders on the commercial side of the business.
"We continue to add talent to our world-class management team with the addition of John and Mark. They bring tremendous experience and capabilities in the areas of distribution strategy and vaccine commercialization," said David M. Mott, chief executive officer and president. "These areas are critical to our future as we work to enhance relationships with our distributor and wholesaler partners, and to develop the optimal strategy for global commercialization of our next-generation formulation of FluMistŪ (influenza Virus Vaccine Live, Intranasal), which we hope to launch in 2007."
John J. Trizzino has been appointed to the new position of vice president, trade and distribution. Mr. Trizzino is responsible for developing and implementing strategies for distribution of MedImmune's current and future products. He is also responsible for managing relationships with wholesalers and distributors. Prior to joining MedImmune, Mr. Trizzino was senior vice president, business development at ID Biomedical. During his tenure at ID Biomedical, Mr. Trizzino negotiated the company's $2.3 billion U.S. influenza vaccine distribution agreement and was responsible for government relations in addition to his business development duties. Previously, he worked for Henry Schein's medical group for eight years in roles of increasing responsibility, including vice president, business development, and vice president and general manager of General Injectables and Vaccines. Mr. Trizzino has more than 24 years of experience in the vaccine industry and has worked closely with public and private partners including the U.S. Centers for Disease Control and Prevention, the Department of Health and Human Services and various vaccine distributors. Mr. Trizzino holds a bachelor of science degree from the C.W. Post Campus, Long Island University, and a master's in business administration from New York University's Leonard N. Stern School of Business.
Mark C. Twyman has been appointed to the new position of vice president and general manager, vaccines. He brings to MedImmune more than 18 years of biopharmaceutical marketing and sales experience, including 15 years in the vaccine industry. In his new role, Mr. Twyman is responsible for the commercial introduction and success of vaccines in MedImmune's portfolio. Previously, Mr. Twyman worked for Merck's Vaccine Division where he held positions of increasing responsibility leading to vice president, global pediatric franchise. Mr. Twyman's experience at Merck included roles in sales management, marketing, managed care, national accounts, international marketing and sales as well as overall responsibility for global marketing of Merck's pediatric vaccines. Mr. Twyman holds a bachelor's degree in economics from Dickinson College in Carlisle, Pennsylvania. He also earned a master's in business administration from the Wharton School at the University of Pennsylvania.
About MedImmune, Inc.
MedImmune strives to provide better medicines to patients, new medical options for physicians, rewarding careers to employees, and increased value to shareholders. Dedicated to advancing science and medicine to help people live better lives, the company is focused on the areas of infectious disease, cancer and inflammatory diseases. With more than 2,200 employees worldwide, MedImmune is headquartered in Maryland. For more information, visit the company's website at http://www.medimmune.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.